Saturday Quack says, "Scrub the Selenium."
Forbes HealthDay News says, "Selenium Supplements Boost Type2 Diabetes Risk."
A selenium /type2 diabetes study published in the August Annals of Internal Medicine started being sensationalized by the press the minute the embargo was lifted. Once again, the headlines misrepresent the study.
Self-reported (key word here) diagnosis of type2 diabetes was a secondary endpoint in a clinical trial designed to look at the benefit of selenium supplementation in prevention of non-melanoma skin cancer in the Eastern US states where selenium levels are lower than the national average. The study participants were white, elderly males with skin cancer; type2 diabetes was a secondary outcome of interest (after thought of the research team and self reported by the study participants), which many researchers believe reduces the strength and relevance of the findings.
In fact, the first author of the study, Saverio Stranges, MD, PhD, said, "The study findings were interesting, but should be considered cautiously because in the general population, very few people, if any, take selenium supplements only, every day, for nearly eight years, so we can't be sure that these findings apply to the public at large."